79 related articles for article (PubMed ID: 18417092)
1. Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010.
Werner U
Ann Endocrinol (Paris); 2008 Apr; 69(2):164-5. PubMed ID: 18417092
[No Abstract] [Full Text] [Related]
2. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.
Thorkildsen C; Neve S; Larsen BD; Meier E; Petersen JS
J Pharmacol Exp Ther; 2003 Nov; 307(2):490-6. PubMed ID: 12975499
[TBL] [Abstract][Full Text] [Related]
3. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
Christensen M; Knop FK; Holst JJ; Vilsboll T
IDrugs; 2009 Aug; 12(8):503-13. PubMed ID: 19629885
[TBL] [Abstract][Full Text] [Related]
4. Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides.
Kim BJ; Zhou J; Martin B; Carlson OD; Maudsley S; Greig NH; Mattson MP; Ladenheim EE; Wustner J; Turner A; Sadeghi H; Egan JM
J Pharmacol Exp Ther; 2010 Sep; 334(3):682-92. PubMed ID: 20498254
[TBL] [Abstract][Full Text] [Related]
5. Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay.
Chen J; Bai G; Yang Y; Geng P; Cao Y; Zhu Y
Peptides; 2007 Apr; 28(4):928-34. PubMed ID: 17267075
[TBL] [Abstract][Full Text] [Related]
6. Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.
Mapelli C; Natarajan SI; Meyer JP; Bastos MM; Bernatowicz MS; Lee VG; Pluscec J; Riexinger DJ; Sieber-McMaster ES; Constantine KL; Smith-Monroy CA; Golla R; Ma Z; Longhi DA; Shi D; Xin L; Taylor JR; Koplowitz B; Chi CL; Khanna A; Robinson GW; Seethala R; Antal-Zimanyi IA; Stoffel RH; Han S; Whaley JM; Huang CS; Krupinski J; Ewing WR
J Med Chem; 2009 Dec; 52(23):7788-99. PubMed ID: 19702274
[TBL] [Abstract][Full Text] [Related]
7. Identification of potent 11mer glucagon-like peptide-1 receptor agonist peptides with novel C-terminal amino acids: Homohomophenylalanine analogs.
Haque TS; Lee VG; Riexinger D; Lei M; Malmstrom S; Xin L; Han S; Mapelli C; Cooper CB; Zhang G; Ewing WR; Krupinski J
Peptides; 2010 May; 31(5):950-5. PubMed ID: 20138099
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.
Miranda LP; Winters KA; Gegg CV; Patel A; Aral J; Long J; Zhang J; Diamond S; Guido M; Stanislaus S; Ma M; Li H; Rose MJ; Poppe L; Véniant MM
J Med Chem; 2008 May; 51(9):2758-65. PubMed ID: 18412318
[TBL] [Abstract][Full Text] [Related]
9. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.
Chen D; Liao J; Li N; Zhou C; Liu Q; Wang G; Zhang R; Zhang S; Lin L; Chen K; Xie X; Nan F; Young AA; Wang MW
Proc Natl Acad Sci U S A; 2007 Jan; 104(3):943-8. PubMed ID: 17213311
[TBL] [Abstract][Full Text] [Related]
10. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
[TBL] [Abstract][Full Text] [Related]
11. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
Claus TH; Pan CQ; Buxton JM; Yang L; Reynolds JC; Barucci N; Burns M; Ortiz AA; Roczniak S; Livingston JN; Clairmont KB; Whelan JP
J Endocrinol; 2007 Feb; 192(2):371-80. PubMed ID: 17283237
[TBL] [Abstract][Full Text] [Related]
12. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
13. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
Day JW; Gelfanov V; Smiley D; Carrington PE; Eiermann G; Chicchi G; Erion MD; Gidda J; Thornberry NA; Tschöp MH; Marsh DJ; SinhaRoy R; DiMarchi R; Pocai A
Biopolymers; 2012; 98(5):443-50. PubMed ID: 23203689
[TBL] [Abstract][Full Text] [Related]
14. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
15. [Glucagon-like peptide-1 receptor agonists].
Kurose T; Seino Y
Nihon Rinsho; 2012 May; 70 Suppl 3():689-92. PubMed ID: 22768599
[No Abstract] [Full Text] [Related]
16. Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.
Willard FS; Wootten D; Showalter AD; Savage EE; Ficorilli J; Farb TB; Bokvist K; Alsina-Fernandez J; Furness SG; Christopoulos A; Sexton PM; Sloop KW
Mol Pharmacol; 2012 Dec; 82(6):1066-73. PubMed ID: 22930710
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 receptor agonists today.
Marre M; Penfornis A
Diabetes Res Clin Pract; 2011 Sep; 93(3):317-27. PubMed ID: 21767888
[TBL] [Abstract][Full Text] [Related]
18. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
Moon HS; Kim MK; Son MH
Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of the beneficial and protective effects of exenatide in diabetic rats.
Lotfy M; Singh J; Rashed H; Tariq S; Zilahi E; Adeghate E
J Endocrinol; 2014 Mar; 220(3):291-304. PubMed ID: 24353307
[TBL] [Abstract][Full Text] [Related]
20. Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
Spellman CW
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S7-15. PubMed ID: 22267302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
